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BACKGROUND: Cervical cancer (CC) annually kills 288000 women worldwide. Unfortunately, responses to chemoradiation are partial
and are of short duration. As anti-EGFR monoclonal antibodies sensitise tumours, we investigated cetuximab’s toxicity plus
chemoradiation on CC cells, which express different EGFR levels.
METHODS: EGFR, HER2, AKT and MAPK expression and phosphorylation status were determined by western blotting. Cytotoxicity
was assessed by MTT or clonogenic assays (CA) in cell lines treated with cetuximab alone or in combinations.
RESULTS: Cetuximab with cisplatin and radiation achieved maximum cytotoxic effects for A431, Caski and C33A cells (high,
intermediate and low EGFR expression, respectively) in CA. Cetuximab efficiently decreased MAPK and AKT phosphorylation in
A431 cells but slightly less in Caski and C33A cells. To check whether further EGFR, HER2 or MAPK inhibition would improve
cetuximab’s cytotoxicity, we combined it with an EGFR tyrosine kinase inhibitor (TKI), trastuzumab or a MEK1/2 inhibitor (PD98059).
In Caski, but not in C33A cells, cetuximab cooperated with the TKI, reducing cell survival and AKT and MAPK phosphorylation.
However, cetuximab with trastuzumab or PD98059 reduced survival and MAPK phosphorylation of both cell lines.
CONCLUSION: Our data suggest that cetuximab combined with chemoradiation, trastuzumab or MAPK inhibitors has useful
applications for CC treatment, independently of EGFR expression.
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Cervical cancer (CC) is a common malignancy which kills 288000
women annually. Radical hysterectomy and radiation therapy are
standard treatments for early-stage invasive CC, whereas pelvic
radiation has been used for locally advanced cancers. Recently, an
improved survival of patients with locally advanced CC was
reported when platinum-based chemotherapy was combined with
radiation treatment (Ota et al, 2007). However, despite technolo-
gical advances, up to 35% of all CC patients will develop persistent/
recurrent/metastatic disease (Bellone et al, 2007).
Infection of human keratinocytes by oncogenic HPV subtypes is
critical for cervical carcinogenesis, however, it is not sufficient for
cancer development. Among other molecular cofactors investi-
gated, epidermal growth factor (EGF) receptor (EGFR) over-
expression is frequent in CC and is an independent predictor of
poor prognosis in advanced stage tumours (Kersemaekers et al,
1999). Epidermal growth factor receptor, a 170-kDa transmem-
brane glycoprotein, belongs to the ErbB/HER family of receptors,
which include HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4).
Ligand binding leads to the formation of homo- or heterodimers
with other members of the family, receptor autophosphorylation
and activation of signalling pathways, which regulate cell proli-
feration, survival and transformation (Citri and Yarden, 2006).
A major EGFR signalling route, the mitogen-activated protein
kinases (MAPK) pathway is often deregulated in cancer cells. The
activation of this pathway, comprised by Ras, Raf, MEK1/2 and
extracellular signal-regulated kinase (ERK)1/2, leads to tumour
development and progression through the activation of transcrip-
tion factors that stimulate cell proliferation and metastasis
(Dhillon et al, 2007; Katz et al, 2007).
Anti-EGFR monoclonal antibodies (MAbs) are important
molecular-targeted drugs for cancer treatment. Among them,
cetuximab (Erbitux), a recombinant chimeric human-murine
MAb, is one of the most promising and clinically effective
(Mendelsohn and Baselga, 2000). It binds EGFR with higher
affinity than the original ligands, preventing receptor activation,
inducing EGFR internalisation and degradation, inhibiting cell
proliferation and angiogenesis and promoting antibody-dependent
cellular cytotoxicity (ADCC; Mendelsohn and Baselga, 2000;
Vincenzi et al, 2008). Cetuximab induces the radiosensitisation
of different cell types both in vitro and in vivo, including head and
neck, lung, colon, ovarian and breast cancer cell lines (Vincenzi
et al, 2008). Another important member of the ErbB family is
HER2, which is often overexpressed in breast, ovarian, colon and
gastric cancer. The recombinant humanised anti-HER2 trastuzu-
mab (Herceptin), has high affinity for HER2 and induces its
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sdownregulation, with inhibition of proliferation of breast cancer
cell lines in vitro and in vivo (Mendelsohn and Baselga, 2000;
Vincenzi et al, 2008).
As far as we know, data on the combination of cetuximab plus
chemoradiation in CC are lacking; thus, in this study, we
determined cetuximab’s activity either alone or combined with
cisplatin and/or radiotherapy towards CC cell lines which express
different levels of EGFR. We observed that an efficient inhibition of
the MAPK pathway is a determinant factor for sensitisation to
cetuximab treatment. Moreover, our data suggest that cetuximab,
given together with chemoradiation, trastuzumab or MAPK
inhibitors, could have important applications to treat CC,
independently of EGFR expression status.
MATERIALS AND METHODS
Cell lines
A431 cell line was kindly provided by Dr Giuseppe Giaccone
(University Hospital Vrije Universiteit, The Netherlands). Caski
and C33A cells were provided by Dr Luisa L Villa (Ludwig Institute
for Cancer Research, Brazil).
Chemicals
Cetuximab was generously provided by Merck KGaA (Darmstadt,
Germany). PD98059 and PD153035 were obtained from Calbio-
chem (Nottingham, UK). Trastuzumab was provided by Instituto
Nacional de Ca ˆncer (Rio de Janeiro, Brazil).
MTT and clonogenic assays
For MTT, cells were incubated with cetuximab or cisplatin at
different concentrations or cetuximab in the presence/absence of
PD98059 (25mM), a MEK1/2 inhibitor (Friday and Adjei, 2008).
After 72h, cells were incubated with MTT reagent (Sigma, St Louis,
MO, USA) and processed as previously described (Meira et al,
2005). Concentrations resulting in cell growth inhibition of 30
(IC30), 50 (IC50) and 80% (IC80) were calculated for cisplatin. For
other treatments, cell viability was expressed as a percentual of
controls (%CT).
For clonogenic assays (CA), cells were either left untreated or
irradiated with a
60Co-THERATRON-780C irradiator (Theratronics,
Canada) and allowed to grow for 14 days. For the evaluation of
cetuximab alone, or with trastuzumab, or with PD153035, a specific
EGFR TKI, cells were incubated with cetuximab (100mgml
 1) and
trastuzumab (10mgml
 1), or with PD153035 (0.1mM) for 72h. For
the combination experiments with chemoradiation, cetuximab
(100mgml
 1) and cisplatin (at different concentrations) were
added, and 6h later, cells were irradiated and maintained at 371C
for 72h. Cells were allowed to proliferate in fresh medium for 10
days and the number of colony-forming units stained with crystal
violet was expressed as the surviving fraction (SF).
Drug interaction analysis
The cytotoxic effects of the combination of cetuximab and
PD98059 or PD153035 or trastuzumab were analysed according
to Fischel et al (2005), in which R means ratio and if Ro0.8, the
association is considered to be synergistic, 0.8 oRo1.2, additive
and R41.2, antagonistic.
Cell-cycle analysis
Cells were incubated alone or in the presence of cetuximab
(100mgml
 1), as previously described (Janmaat et al, 2003). After
24h, cell-cycle phase distribution was analysed by flow cytometry
using propidium iodide (PI) staining and the resulting DNA
content were analysed on a Becton Dickinson FACScalibur using
ModFitLT V2.0 software (Becton Dickinson, CA, USA).
Hoechst staining
Cells monolayers were treated with cetuximab (100mgml
 1)f o r2 4h
and DNA was stained with Hoechst 33342 (Sigma). Morphological
signs of apoptosis were analysed in duplicate by fluorescence
microscopy and each experiment was repeated at least three times.
Western blotting analysis
Cells were incubated for 4h in the presence of cetuximab
(100mgml
 1) alone or followed by a 15-min incubation with
EGF (10ngml
 1) as previously described (Meira et al, 2009). For
combination experiments, cells were treated as described above,
plus 4h of incubation with trastuzumab (10mgml
 1), or 1h of
incubation with PD98059 (25mM) or PD153035 (0.1mM) alone or
combined with cetuximab before the incubation with EGF. As
C33A cells express low levels of EGFR, more protein was loaded
(80mg, as opposed to 50mg for the other cells) on the gels to
observe the phosphorylation status of the receptor. Primary
antibodies against total and phosphorylated EGFR, HER2, AKT
and MAPK (all from Cell Signaling Technology, Beverly, MA, USA)
were used. Immunoblots were detected using the enhanced
chemiluminescence (ECL) reagent (GE Health Care, Sa ˇo Paulo
Brazil) and bands were quantified with Labworks, version 4.6
(Bio-Rad, USA).
EGFR mRNA expression by real-time RT-PCR
Total RNA was isolated from cell lines and used for reverse
transcription (RT). Real-time RT-PCR was performed with the
QuantiTect SYBR Green PCR Master Mix (Qiagen, Valencia, CA,
USA) and the relative expression level of EGFR mRNA was
calculated using the comparative CT method (DDCT) as described
elsewhere (Livak and Schmittgen, 2001).
EGFR cell surface expression by flow cytometry
As previously described (Meira et al, 2009), cells were incubated either
with a murine anti-EGFR Mab (0.1mgml
 1;B DP h a r m i n g e n ,S a n
Diego, CA, USA) or cetuximab (0.1mgml
 1) for 1h on ice. After
washing, secondary antibodies (Caltag Laboratories, Burlingame, CA,
USA) were added and samples were analysed on a FACScalibur using
CELLQuest software (Becton Dickinson, San Jose, CA, USA).
In vitro ADCC assay
Antibody-dependent cellular cytotoxicity assay was performed
with the kit CytoTox 96 Non-Radioactive Cytotoxicity Assay
(Promega, Madison, WI, USA). Cells were incubated alone or in
the presence of 4mgml
 1 of cetuximab for 4h and exposed to
peripheral blood mononuclear cells (PBMC) at effector/target
ratios (E/T) of 20:1 for 4h and specific cytolysis (ADCC) was
measured as previously described (Meira et al, 2009).
Determination of VEGF secretion
Cells were incubated alone or in the presence of cetuximab
(100mgml
 1) for 24 or 48h. VEGF protein concentration in the
culture medium was determined using human VEGF ELISA
Development Kit (Peprotech Inc., Rock Hill, NJ, USA).
Statistical analysis
All experiments were done in triplicate and the values represent an
average of at least three independent experiments. Statistical
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sanalyses were performed using GraphPad Prism 3.0 (GraphPad
Software Incorporated, CA, USA). Quantitative experiments were
analysed by Student’s t-test. One-way analysis of variance
(ANOVA) with Tukey’s post test was used to analyse the
combination of cetuximab, cisplatin and RxT vs double or
individual treatments by CA. All P values resulted from the use
of two-sided tests and were considered significant when o0.05.
RESULTS
Differential effects of RxT, cisplatin and cetuximab on cell
proliferation and cell-cycle kinetics
We examined the antiproliferative effects of isolated RxT, cisplatin
and cetuximab treatments on A431, Caski and C33A cells (Figures
1A–F), which express high to low EGFR levels, respectively (see
Figures 3A and 5A). A431 growth is impaired by EGFR inhibitors
(Janmaat et al, 2003), so we used this cell line for comparison with
the CC cell lines. A431 and Caski cells showed similar resistance to
RxT and low cisplatin concentrations (IC30) in CA and MTT assays
(Figures 1A and B), but Caski cells showed increased resistance at
higher cisplatin concentrations (IC50 and IC80; Figure 1B). C33A
cells were, in turn, quite sensitive to both treatments (Figures 1A
and B). Cetuximab treatment decreased the viability of all cell lines
in CA and MTT experiments at all concentrations tested (Figures
1C and D). These effects were related to an increase of 14.1, 12.6
and 6.5% in cell number at G0/G1 for A431, Caski and C33A cells
on cetuximab treatment, respectively (Figure 1E) and a decrease in
the population of cells at S and G2/M phases when compared to
controls (CT; Figure 1E).
Apoptotic cells are usually found in the sub-G1 phases and,
accordingly, 24-h cetuximab treatment increased this cell popula-
tion by 4.6, 3.9 and 2.9% in A431, Caski and C33A cells, respec-
tively (Figure 1E). Additionally, apoptotic cells were also observed
by Hoechst staining in all cell lines after cetuximab treatment
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Figure 1 Effect of RxT, cisplatin or cetuximab treatments on the proliferation and cell-cycle distribution of A431, Caski and C33A cells. (A) Effects of
different doses of RxT in clonogenic assays (CA). (B) Effects of different concentrations of cisplatin in MTT assay. (C) Effects of cetuximab (100mgml
 1)i n
CA. (D) Effects of cetuximab treatment in MTT assay. (E) Effects of cetuximab treatment (100mgml
 1) on cell-cycle phase distribution analysis by flow
cytometry. (F) Induction of apoptotic bodies by cetuximab treatment (100mgml
 1) visualised by Hoechst staining. Student’s t-test *Po0.05, compared to
controls.
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s(Figure 1F) and, even in C33A cells, which express low EGFR levels,
a reduction of 21% in cell proliferation was obtained, especially at
high MAb concentration (100mgml
 1; Figure 1D).
Cetuximab induces chemo/radiosensitisation of CC cells
We evaluated whether the combination of cetuximab (100mgml
 1)
with RxT and/or cisplatin could enhance the cytotoxic effects
observed in CA. Isolated cetuximab, cisplatin and RxT treatments
decreased the survival of all cell lines (Figures 2A–D) but the
combination of cetuximab with either RxT or cisplatin enhanced
these effects (Po0.05). Furthermore, the triple combination of
cetuximab, cisplatin and RxT achieved maximum effects for all cell
lines in CA (demonstrative pictures of A431 cells are shown in
Figure 2D). Caski cells are HPV-positive and express intermediate
levels of EGFR and HER2, resembling typical CC tumours. In this
cell line, the triple combination reached up to 70% inhibition in
CA (Figure 2B) whereas in C33A cells, an inhibition of 60% was
observed (Figure 2C).
The CC cell lines express different basal levels of total and
phosphorylated EGFR, HER-2, AKT and ERK1/2
A431 cells strongly express EGFR (Janmaat et al, 2003) whereas
Caski and C33A cells show moderate and low expression levels,
respectively (Figure 3A). Additionally, we confirmed EGFR
expression by real-time RT-PCR and by FACS analysis. The
relative EGFR mRNA level of A431 is high and Caski cells express
two times more EGFR than C33A (Figure 5A). Moreover, FACS
analysis showed that both a murine anti-EGFR MAb and
cetuximab could detect high EGFR expression on the surface of
A431 cells and intermediate and low levels in Caski and C33A cells,
respectively (Figure 5B). HER2 expression was more homogenous
among the cell lines with Caski and C33A cells expressing 20 and
40% more HER2 than A431 cells, respectively. The basal phos-
phorylation status of EGFR and HER2 was inversely correlated,
with higher levels of p-EGFR in A431 cells and higher levels of
p-HER2 in C33A and Caski cells (Figure 3A).
On EGF binding, the major signalling pathways activated are the
MAPK and AKT cascades (Citri and Yarden, 2006). A431 and Caski
cells show low basal levels of p-AKT whereas C33A cells have
a much higher level. A431 and C33A cells had higher levels of
activated ERK1/2 (p-p44/42 MAPK) but no significant differences
in total MAPK were observed among the cell lines (Figure 3A).
Cetuximab inhibits EGFR and HER2 phosphorylation
To investigate the molecular determinants for cetuximab’s effects
in MTT and CA, we analysed EGFR phosphorylation by WB in cells
treated with cetuximab (100mgml
 1) alone or in the presence of
EGF. Receptor phosphorylation was increased by EGF in A431 and
Caski cells, whereas cetuximab reduced it (Figures 3B and C).
Epidermal growth factor and cetuximab also induced a slight
decrease in the total amount of EGFR in these cells (Figures 3B
and C).
Epidermal growth factor receptor can interact with another
member of the ErbB family, HER2, to form heterodimers that are
very potent in activating signal transduction pathways (Citri and
Yarden, 2006). On cetuximab treatment there were no changes in
total HER2 in the CC cell lines, whereas EGF-induced HER2
phosphorylation was inhibited in A431 and Caski cells (Figures 3B
and C). Interestingly, in C33A cells, which express more HER2
than EGFR (Fig 3A), cetuximab markedly reduced EGF-induced
HER2 phosphorylation (Figure 3D).
There were no changes in total AKT and MAPK proteins in all
cell lines on cetuximab treatment (Figures 3B–D). Epidermal
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sgrowth factor increased AKT and ERK1/2 phosphorylation in A431
and Caski cells but in C33A cells there was only a slight increase.
This was not unexpected, because both pathways are activated in
this cell line (Figure 3A). Cetuximab inhibited EGF-induced AKT
phosphorylation more strongly in A431 cells and less so in Caski
and C33A cells. Indeed, it markedly reduced EGF-induced ERK1/2
phosphorylation in A431 cells, but in Caski and C33A cells the
reduction was more modest (60 and 20% inhibition, respectively;
Figures 3B–D), suggesting that persistent signalling through these
pathways led to increased survival of Caski and C33A cells, when
compared to A431 cells in the presence of cetuximab.
Cetuximab combined with trastuzumab synergistically
reduces cell proliferation and activation of downstream
signalling pathways in CC cells
We speculated that cells expressing higher EGFR/HER2 ratios,
such as A431 cells, rely more on EGFR signalling for MAPK
pathway activation and cell proliferation, whereas cells with a
lower EGFR/HER2 ratio, such as C33A cells, depend more on
EGFR/HER2 heterodimer signalling. Based on this assumption,
the inhibition of the EGFR/HER2 heterodimer by anti-EGFR
(cetuximab) and anti-HER2 (trastuzumab) MAbs should interfere
with C33A cell proliferation. As expected, this combination
markedly reduced C33A cell colony formation leading to a syner-
gistic interaction (R¼0.58; Figures 4A and B), with concomitant
reduction of MAPK and AKT phosphorylation (Figure 4D). Indeed,
an additive effect (R¼0.84) was also noted for Caski cells, that
express intermediate levels of EGFR and HER2 (Figure 3A), with a
decrease of almost 60% in cell survival (Figures 4A and B) and
inhibition of downstream signalling pathways (MAPK and AKT;
Figure 4C). There were no changes in total AKT and MAPK proteins
in Caski and C33A cell lines on treatments (data not shown).
The combination of cetuximab with a TKI inhibits cell
proliferation and MAPK phosphorylation in Caski but not
in C33A cells
Based on the idea of an EGFR/HER2 heterodimer signalling
dependency of C33A cells, we investigated whether further EGFR
inhibition with another targeted drug, such as TKIs, affected more
Caski than C33A cells. Therefore, we tested the combination of
cetuximab with a specific EGFR TKI (PD153035). As expected,
combined treatments reduced Caski cell survival leading to an
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sadditive interaction (R¼0.94) when compared to treatments alone
(Figure 4E). Additionally, the double treatment in Caski cells was
accompanied by a greater reduction of EGFR, HER2, AKT and
MAPK phosphorylation (Figure 4G).
Isolated cetuximab or PD153035 treatments reduced the survival
of C33A cells in CA by the same proportion, reaching a more
modest inhibition of HER2, AKT and MAPK phosphorylation than
in Caski cells (Figures 4E and G). In contrast, the combined
treatment proved to be antagonistic (R¼1.28), with no decrease in
phosphorylated proteins when compared to either drug alone
(Figures 4E and G). Altogether, these data corroborate with our
hypothesis that C33A cells are not so dependent on EGFR
signalling for proliferation, as double EGFR inhibition with
different drugs did not enhance the toxicity achieved by either
agent alone. Additionally, the targeting of EGFR and HER2 with
two different MAbs showed synergistic inhibitory effects (Figures
4A and B) demonstrating that heterodimer signalling is necessary
for C33A cell proliferation. Furthermore, these data indicate that
the successful inhibition of the MAPK and/or AKT pathways is a
determinant factor for cetuximab efficacy in all CC cell lines.
Cetuximab combined with PD98059 synergistically reduces
cell proliferation and MAPK pathway activation in CC cells
To confirm that the MAPK pathway is relevant for cetuximab
response, drug combination experiments with PD98059 (MEK1/2
inhibitor) were performed. Both treatments inhibited Caski and
C33A cell proliferation by the same magnitude, with a reduction of
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Figure 4 Effects of cetuximab (100mgml
 1) alone or combined with trastuzumab (10mgml
 1), an anti-HER2 MAb, or PD153035 (0.1mM), an EGFR
tyrosine kinase inhibitor, or PD98059 (25mM), a MAPK pathway inhibitor, on Caski and C33A cells. (A) Effects of cetuximab alone or combined to
trastuzumab on the survival in CA. (B) Representative pictures of Caski and C33A cells under cetuximab and trastuzumab treatments in CA. (C and D)
Western blotting analysis of the inhibition of EGF-induced phosphorylation of AKT and p44/42 (ERK1/2) by cetuximab alone or combined with trastuzumab
in Caski and C33A cells, respectively. (E) Effects of cetuximab alone or combined with PD153035 on cell survival in CA. (F) Effects of cetuximab alone or
combined with PD98059 on proliferation by MTT assays. (G) Western blotting analysis of the inhibition of EGF-induced phosphorylation of EGFR
(Tyr1068), HER-2/neu, AKT and p44/42 (ERK1/2) by cetuximab alone or combined with PD153035. To visualise EGFR in C33A cells, 80mg of protein were
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phosphorylation of p44/42 (Erk1/2) by cetuximab and PD98059. Student’s t-test *Po0.05, when compared to control cells. (I) Proposed model of the
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through EGFR and triggers the AKT and MAPK pathways. The binding of cetuximab sensitises CC cells to chemoradiation (1) and to trastuzumab (2), leading
to cell death independently of EGFR expression levels, but more dependent on EGFR-HER2 signalling. For cells in which activation of the MAPK pathway
occurs also through EGFR independent mechanisms, cetuximab inhibition of EGFR sensitises them to PD98059 (3), a MAPK pathway inhibitor, leading to
additive effects on the inhibition of cell proliferation.
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s50% and an additive effect for the combination over single-drug
treatment in both cell lines (R¼0.88 and R¼0.92, respectively;
Figure 4F). As expected, Figure 4H shows that a strong inhibition
of MAPK phosphorylation was seen in both cell lines on treatment
with PD98059 alone or in combination with cetuximab. As the
combination of both treatments led to a near complete MAPK
cascade blockage, accompanied by a significant reduction of CC
cell proliferation, we confirmed that the inhibition of this pathway
plays an important role in cetuximab’s efficacy.
Cetuximab induces ADCC in A431 and Caski, but not in
C33A cells
Antibody-dependent cellular cytotoxicity response is dependent on
the number of EGFR molecules per cell and on how efficiently
cetuximab recognises its target (Vincenzi et al, 2008). FACS
analysis showed that cetuximab detected even more cell surface
receptors in A431 and Caski cells (Po0.05), when compared to a
commercially available murine anti-EGFR MAb, although the same
was not observed for C33A cells (Figure 5B). Accordingly, at E/T
ratios of 20:1, cetuximab mediated ADCC in 26.4 and 15.1% of
A431 and Caski cells, respectively, but not in C33A cells (1.75%;
Figure 5C).
Cetuximab and RxT cooperate in an additive manner to
inhibit VEGF secretion
Anti-EGFR MAbs show suppressive effects on VEGF expression
in vitro and in vivo (Vincenzi et al, 2008; Meira et al, 2009).
To examine whether cetuximab (100mgml
 1) had this effect in CC
cells, we tested it alone or combined with RxT (5Gy) and VEGF
expression was analysed by ELISA. Cetuximab or RxT treatments
decreased VEGF secretion in all cell lines (Figures 5D–F; Po0.05).
The combination of cetuximab with RxT for 24h had an additive
effect and, after 48h of treatment, a further reduction was observed
(Figures 5D–F), suggesting that these treatments have the
potential of interfering with angiogenesis even in cells that do
not express high EGFR levels.
DISCUSSION
In the past two decades we have seen the successful development
of EGFR-targeted drugs, expanding treatment options for cancer
patients. Cetuximab is currently being tested in preclinical and
clinical studies worldwide to treat several types of cancer.
Unfortunately, several issues still remain unaddressed, such as
which patients are most likely to have a therapeutic benefit, what
are the predictive factors of sensitisation or response to these
agents and, most importantly, which are the best strategies for
combination with conventional treatments.
Available data suggest that cetuximab enhances chemotherapy
and radiotherapy’s effects and reverses resistance to some anti-
cancer drugs (Merlano and Occelli, 2007). Cetuximab’s blockage
of EGFR signalling sensitises several types of cells to RxT (Mendelsohn
and Baselga, 2000; Vincenzi et al, 2008) and the combination of
cetuximab with cisplatin is effective and tolerable to patients
(Mendelsohn and Baselga, 2000; Merlano and Occelli, 2007). Our
data demonstrated that cetuximab sensitised all tested CC cell lines to
RxT and cisplatin treatment, independently of EGFR expression.
Recently, it has been shown that EGFR-negative colon tumours
have the potential to respond to cetuximab-based therapies
(Chung et al, 2005). Moreover, it was demonstrated that HER2
signalling could mediate resistance to TKI in breast cancer cell
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slines due to the activation of alternative EGFR family receptors
(Kong et al, 2008). In accordance, EGFR promoted dimerisation
and strong activation of HER2 in cells, which acquired cetuximab
resistance, with consequent activation of downstream cascades
and sustained proliferation (Wheeler et al, 2008). These studies
suggest that EGFR is responsible for transphosphorylation of
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to cetuximab’s therapeutic effects. Our data confirmed this
hypothesis, because the double inhibition of EGFR and HER2 by
cetuximab and trastuzumab further decreased Caski and C33A cell
proliferation. Additionally, the response to these drug combina-
tions does not seem to rely solely on EGFR expression levels but
also on an effective inhibition of HER family members and of
downstream signalling pathways.
In Caski cells, the isolated treatment with cetuximab and with
the TKI PD153035 or their combination diminished survival in
CA (Figure 4E). However, in C33A cells this combination was
antagonic (Figure 4E). This antagonism has also been demon-
strated when cetuximab was combined with ZD 1839 (TKI) in head
and neck cell lines (Fischel et al, 2005). As described for colon,
breast and lung cell lines (Mendelsohn and Baselga, 2000; Janmaat
et al, 2003; Matar et al, 2004) the success of the combination of
MAbs with TKIs was due to an efficient inhibition of EGFR, HER2,
AKT and MAPK phosphorylation, corroborating our observations
for Caski cells (Figure 4G). In C33A cells, however, the
combination of cetuximab plus PD153035 failed because it did
not bring any further reduction in AKT or MAPK activation
(Figure 4G).
Recent data described that CC progression was correlated with
MAPK pathway activation, showing that this cascade has an
important role in CC development (Chen et al, 2007; Perez-
Plasencia et al, 2007). Clinical studies done with MEK inhibitors
have examined only single agent effects (Friday and Adjei, 2008)
and the combinations with cytotoxic agents are likely to be
beneficial for cancer treatment. The importance of the MAPK
cascade for CC cell survival was demonstrated when we combined
a specific MEK1/2 inhibitor (PD98059) with cetuximab, resulting
in an additive inhibition of Caski and C33A cell proliferation.
Indeed, based on the basal levels of relevant signalling molecules,
we suggest that blockage of p-EGFR, p-HER2 and p-MAPK are
predictive factors for cetuximab sensitisation. In accordance, a
recent study of head and neck cancer demonstrated that activation
of EGFR and HER2 was correlated with MAPK activation and that
ERK1/2 inhibition by cetuximab points to these molecules as
potential surrogate markers in the clinical setting (Albanell
et al, 2001). Based on this, we proposed a model of cetuximab’s
effects in combination with chemoradiation, trastuzumab or
MAPK pathway inhibitors on CC cell lines (Figure 4I). Firstly,
our data support the idea that combination of cetuximab with
chemoradiation is an interesting approach to treat CC, irrespective
of EGFR expression. Secondly, this study reported that cetuximab’s
effects are influenced by HER2 expression and the use of
cetuximab in combination with trastuzumab could decrease CC
cell survival. Thirdly, we observed that MAPK pathway activation
was dominant for CC cell survival and that the blockage of both
pathways (EGFR/MAPK) acts synergistically in inhibiting cell
proliferation.
Anti-EGFR MAbs can also downregulate VEGF expression
(Mendelsohn and Baselga, 2000; Vincenzi et al, 2008; Meira et al,
2009) and, accordingly, cetuximab alone or with RxT reduced
VEGF protein secretion in all cells, indicating the potential role of
this combination in the inhibition of angiogenesis in vivo.
Antibody-dependent cellular cytotoxicity activity is another
important anticancer mechanism induced by cetuximab in various
cell lines (Bellone et al, 2007; Meira et al, 2009) and this MAb
effectively induced ADCC in A431 and Caski cells, whereas no
ADCC was observed in the C33A cell line. Based on these findings
we conclude that cell surface EGFR expression is very relevant for
cetuximab induction of ADCC, but not as much for inhibiting
VEGF secretion and cell proliferation, demonstrating that cetux-
imab can modulate multiple crucial pathways of CC cell lines in
different ways.
In summary, our data suggested that the combination of
cetuximab with cisplatin/ RxT, trastuzumab or with MAPK
inhibitors could be useful for CC treatment, independently of
EGFR expression status. Our preclinical data are encouraging
and we hope that these results can be translated into the
clinical setting. We believe that appropriately designed clinical
trials are required to define the optimum doses and sequence of
treatments, and will be interesting to first try these combinations
in animal models. Indeed, the understanding of the relative
contribution of individual members of the ErbB receptor family
and activated downstream pathways in cervical cancer cell
proliferation is far from complete, and further validation of our
results in experiments involving primary cervical tumours in vitro
are desired.
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